Amneal Pharmaceuticals, Inc. revenue by segment AMRX

Amneal Pharmaceuticals, Inc. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Affordable Medicines at $489.9 million, 62% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Revenue
3,118
796
723
814
785
725
695
731
702
Affordable Medicines
—
490
+13.0%
share 61.5%
423
+2.1%
share 58.6%
—
—
433
share 59.8%
415
share 59.6%
—
—
Av KARE
—
157
-3.7%
share 19.7%
166
-3.7%
share 23.0%
211
+23.7%
share 25.9%
199
+24.5%
share 25.3%
163
share 22.5%
172
share 24.8%
170
share 23.3%
159
share 22.7%
Specialty
—
149
+16.6%
share 18.8%
—
167
+38.1%
share 20.5%
125
+8.3%
share 16.0%
128
share 17.7%
—
121
share 16.5%
116
share 16.5%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AMRX (Nasdaq)
Fiscal year ends
December 31
SEC filer status
Large accelerated filer
SEC CIK
1723128
Former names
Atlas Holdings, Inc. (until Apr 13, 2018)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.